Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intralesional rituximab for cutaneous B-cell lymphoma
Autore:
Paul, T; Radny, P; Krober, SM; Paul, A; Blaheta, HJ; Garbe, C;
Indirizzi:
Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany Univ Tubingen Tubingen Germany D-72076 rmatol, D-72076 Tubingen, Germany Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany Univ Tubingen Tubingen Germany D-72076 Pathol, D-72076 Tubingen, Germany
Titolo Testata:
BRITISH JOURNAL OF DERMATOLOGY
fascicolo: 6, volume: 144, anno: 2001,
pagine: 1239 - 1243
SICI:
0007-0963(2001)144:6<1239:IRFCBL>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTI-CD20 MONOCLONAL-ANTIBODY; NON-HODGKINS-LYMPHOMA; LOW-GRADE; BORRELIA-BURGDORFERI; PHASE-II; THERAPY; ORIGIN; SKIN; RADIOTHERAPY; CD20;
Keywords:
cutaneous B-cell lymphoma; intralesional therapy; rituximab;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Garbe, C Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany Univ Tubingen Liebermeisterstr 25 Tubingen Germany D-72076 rmany
Citazione:
T. Paul et al., "Intralesional rituximab for cutaneous B-cell lymphoma", BR J DERM, 144(6), 2001, pp. 1239-1243

Abstract

Rituximab, a chimeric anti-CD20 monoclonal antibody, has been approved forsystemic treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. As cutaneous B-cell lymphoma (CBCL) also expresses the CD20molecule, three patients with histologically and immunohistochemically confirmed CBCL without systemic involvement were treated with low-dose intralesional rituximab in a pilot study. Single doses applied ranged from 10 to 30 mg per lesion, according to lesion extent, with a cumulative dose of up to 350 mg. Injections were given two or three times weekly for 3-5 weeks, with a second cycle after 6 weeks in one patient with incomplete remission. Complete and lasting remission was achieved in each patient; this has persisted for up to more than 1 year. The observed adverse events were of grade 1severity. Results suggest that intralesional rituximab may be a safe and effective new therapy modality for CBCL.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 09:44:14